Literature DB >> 2095186

Efficacy of intravenous immunoglobulins in sclerodermatomyositis.

C Bodemer, D Teillac, M Le Bourgeois, B Wechsler, Y de Prost.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2095186     DOI： 10.1111/j.1365-2133.1990.tb01462.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.

Authors:  Corrie L Poelman; Laura K Hummers; Fredrick M Wigley; Cynthia Anderson; Francesco Boin; Ami A Shah
Journal:  J Rheumatol       Date:  2014-11-29       Impact factor: 4.666

Review 2.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 3.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 4.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

5.  The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis.

Authors:  Marta Baleva; Krasimir Nikolov
Journal:  Int J Rheumatol       Date:  2011-11-02

Review 6.  Emerging treatments for scleroderma/systemic sclerosis.

Authors:  Jane L Zhu; Samantha M Black; Henry W Chen; Heidi T Jacobe
Journal:  Fac Rev       Date:  2021-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.